Experts indicate that this rare disorder can lead to various uncomfortable symptoms, including nausea, vomiting, bloating, ...

Vanda Pharmaceuticals Inc. VNDA announced that the FDA issued a complete response letter (CRL) to its new drug application ...

Vanda was seeking the health regulator's nod for the drug, tradipitant, to treat symptoms of gastroparesis, a condition ...

The US FDA has declined to approve the NDA submitted by Vanda Pharmaceuticals for tradipitant to treat gastroparesis symptoms ...

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...

Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesisSOLANA BEACH, Calif., Sept.

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Vanda Pharmaceuticals regarding the New Drug Application (NDA) for tradipitant for the treatment of gastroparesis.

Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...

Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.’s (NASDAQ:VNDA) New Drug Application (NDA) of tradipitant ...